

2010 CCS Antiplatelet Guidelines: The Use of Antiplatelet Therapy in the Outpatient Setting

Disclosures of Conflict of Interests

Member	Has an affiliation with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline	Consulting fees/ Honoraria	Officer, director, or in any other fiduciary role	Clinical Trials	Ownership/ partnership/ principal	Intellectual property rights	Other financial benefit
Alan D. Bell	Yes	AstraZeneca, Boehringer Ingelheim, sanofi-aventis,	None	Bayer, Daiichi Sankyo Inc	None	None	None
André Roussin	No	AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Merck, Pfizer, Schering Plough, sanofi-aventis	None	Bayer, sanofi-aventis, Bristol-Myers Squibb, Investigator Pharma	None	None	None
Raymond Cartier	No	None	None	None	None	Yes	None
Wee Shian Chan	Yes	sanofi-aventis	None	None	None	None	None
James D. Douketis	Yes	Boehringer Ingelheim Leo Pharma Pfizer	None	None	None	None	None
Anil Gupta	Yes	AstraZeneca Bristol-Myers Squibb Merck, Novartis, Pfizer, sanofi-aventis, Servier	None	None	None	None	None
Maria E. Kraw	No	None	None	None	None	None	None
Thomas F. Lindsay	Yes	sanofi-aventis	None	None	None	None	None
Michael P. Love	Yes	Abbott Vascular, AstraZeneca	None	None	None	None	None
Neesh Pannu	No	None	None	None	None	None	None
Rémi Rabasa-Lhoret	Yes	AstraZeneca, Eli Lilly, GlaxoSmithKline, Novartis, Abbott, Imunotec, Merck, Novo-Nordisk, sanofi-aventis,	None	Consortium Québécois du Médicament, Cystic Fibrosis Foundation, Quebec Diabetes Association, CIHR, Merck, Novo-Nordisk, sanofi-aventis	None	None	None

2010 CCS Antiplatelet Guidelines: The Use of Antiplatelet Therapy in the Outpatient Setting

Disclosures of Conflict of Interests

Member	Has an affiliation with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline	Consulting fees/ Honoraria	Officer, director, or in any other fiduciary role	Clinical Trials	Ownership/ partnership/ principal	Intellectual property rights	Other financial benefit
Ashfaq Shuaib	Yes	CoAxia, Merck, sanofi-aventis, Servier, Boehringer Ingelheim, Pfizer, AstraZeneca, Roche	None	None	None	None	None
Philip Teal	No	Boehringer Ingelheim, Bristol-Myers Squibb, sanofi-aventis	None	None	None	None	None
Pierre Thérout	Yes	GlaxoSmithKline	None	None	None	None	None
A. Graham Turpie	Yes	sanofi-aventis, Bayer, GlaxoSmithKline, Johnson & Johnson, Pfizer	None	None	None	None	None
Robert C. Welsh	Yes	Bristol-Myers Squibb, Eli Lilly, AstraZeneca, sanofi-aventis, Roche, Canadian Medical Protection Association	None	AstraZeneca, Boehringer Ingelheim, Eli Lilly, sanofi-aventis, Portola, Johnson & Johnson, Regada, Roche	None	None	None
Jean-François Tanguay	Yes	Boehringer Ingelheim, Abbott Vascular, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, sanofi-aventis	None	Accumetrics, Abbott Vascular, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, sanofi-aventis	None	None	None